Genentech, Inc. Share Price

Stocks

End-of-day quote NYSE Other stock markets
- ^USD	-

16/02/15	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
29/11/-1	GENENTECH : profit rises, sales top estimates	RE

16/02/15	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
29/11/-1	GENENTECH : profit rises, sales top estimates	RE
29/11/-1	GENENTECH : 3rd-quarter profit rises	RE
29/11/-1	GENENTECH : rejects Roche bid but willing to talk	RE
29/11/-1	GENENTECH : rejects Roche bid	RE
29/11/-1	GENENTECH : Roche buys Genentech for $46.8 billion	RE
29/11/-1	GENENTECH : Roche increases Genentech offer to $45.7 billion	RE
29/11/-1	GENENTECH : gives long-term forecast to fend off Roche	RE
29/11/-1	GENENTECH : to make case for higher purchase price	RE
29/11/-1	GENENTECH : asks shareholders to hold off on Roche bid	RE
29/11/-1	GENENTECH : Roche goes hostile, cuts Genentech bid to $42 billion	RE
29/11/-1	GENENTECH : forecast disappoints	RE
29/11/-1	GENENTECH : profit up, forecast light	RE

20/04/11	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
20/04/11	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
29/11/-1	GENENTECH : Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash	PR
29/11/-1	Genentech : Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer	BU
29/11/-1	Genentech : CORRECTING and REPLACING Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox	BU

12/04/16	Roche: la FDA homologue Venetoclax pour traiter une sorte de leucémie
11/04/16	Roche erhält von FDA Zulassung für Venetoclax zur Behandlung von Leukämie-Art
29/11/-1	Genentech : accroît de 7% son résultat net trimestriel.
29/11/-1	Genentech : l'offre de Roche considérée comme insuffisante.
29/11/-1	Genentech : s'envole après l'offre de Roche.

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.60%	+2.02%	+56.34%	+168.94%	1,102B
JOHNSON & JOHNSON	-1.44%	+3.71%	+69.07%	+65.40%	643B
ABBVIE INC.	-0.75%	+0.67%	+33.18%	+86.52%	450B
ROCHE HOLDING AG	-1.35%	+1.86%	+29.96%	+26.28%	336B
ASTRAZENECA PLC	-0.86%	+2.79%	+37.72%	+40.85%	298B
NOVARTIS AG	-0.71%	+0.72%	+28.85%	+48.27%	288B
NOVO NORDISK A/S	-1.31%	-0.26%	-28.18%	-39.82%	222B
AMGEN INC.	-0.03%	+1.84%	+23.90%	+68.30%	199B
GILEAD SCIENCES, INC.	-0.40%	+7.82%	+22.29%	+82.50%	169B
Average	-0.94%	+2.96%	+30.35%	+60.81%	411.78B
Weighted average by Cap.	-1.16%	+2.71%	+41.37%	+86.55%

Employees

Sector